Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality [Hematologic Malignancy]
Conclusion
Pretransplantation Mog was significantly associated with an increased risk of GVHD-related mortality, which supports the relevance of CCR4-expressing Tregs after allo-HSCT in humans. In clinical practice, Mog should be cautiously used for patients with ATLL who are eligible for allo-HSCT.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Fuji, Inoue, Utsunomiya, Moriuchi, Uchimaru, Choi, Otsuka, Henzan, Kato, Tomoyose, Yamamoto, Kurosawa, Matsuoka, Yamaguchi, Fukuda Tags: Lymphoma Hematologic Malignancy Source Type: research
More News: Acute Leukemia | Cancer & Oncology | Chemotherapy | Corticosteroid Therapy | Hematology | Leukemia | Lymphoma | Stem Cell Therapy | Stem Cells | Transplants